Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CRIS

CRIS - Curis Inc Stock Price, Fair Value and News

$0.93-0.02 (-2.11%)
Market Closed

6/100

CRIS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

6/100

CRIS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.75

Target 3M

$0.85

Target 6M

$0.8

CRIS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CRIS Price Action

Last 7 days

3.3%

Last 30 days

-10.6%

Last 90 days

-37.6%

Trailing 12 Months

-70.3%

CRIS RSI Chart

CRIS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CRIS Valuation

Market Cap

12.0M

Price/Earnings (Trailing)

-0.33

Price/Sales (Trailing)

1.03

Price/Free Cashflow

-0.4

CRIS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.75

Target 3M

$0.85

Target 6M

$0.8

CRIS Fundamentals

CRIS Revenue

Revenue (TTM)

11.7M

Rev. Growth (Yr)

8.36%

Rev. Growth (Qtr)

15.53%

CRIS Earnings

Earnings (TTM)

-36.6M

Earnings Growth (Yr)

23.41%

Earnings Growth (Qtr)

10.05%

CRIS Profitability

Return on Equity

248.83%

Return on Assets

-132.25%

Free Cashflow Yield

-250.25%

CRIS Investor Care

Shares Dilution (1Y)

52.70%

Diluted EPS (TTM)

-3.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202511.2M11.4M11.7M0
20249.8M10.2M10.3M10.9M
202310.4M10.2M10.2M10.0M
202210.5M10.6M10.4M10.2M
202110.3M10.2M10.5M10.6M
202010.9M11.2M11.1M10.8M
20199.7M9.5M9.5M10.0M
201810.2M10.5M10.9M10.4M
20177.9M8.3M9.0M9.9M
20167.9M7.5M7.3M7.5M
201510.2M7.5M7.8M7.9M
201415.4M14.8M9.4M9.8M
20137.5M8.5M15.2M15.0M
201219.6M24.5M29.4M17.0M
201115.7M15.4M15.1M14.8M
201000016.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Curis Inc

CRIS
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with solid tumors and lymphomas; and CA-327, a pre-clinical development candidate, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma; and Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
 CEO
 WEBSITEcuris.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES51

Curis Inc Frequently Asked Questions

CRIS is the stock ticker symbol of Curis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Curis Inc is 12.02 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CRIS's fair value in chart for subscribers.

The fair value guage provides a quick view whether CRIS is over valued or under valued. Whether Curis Inc is cheap or expensive depends on the assumptions which impact Curis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRIS.

As of Wed Jan 28 2026, CRIS's PE ratio (Price to Earnings) is -0.33 and Price to Sales (PS) ratio is 1.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRIS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Curis Inc has provided -0.196 (multiply by 100 for percentage) rate of return.